HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Church & Dwight Takes Homeopathic Turn For OTC Sales Driver, Acquires Zicam Marketer Matrixx

Executive Summary

C&D CEO Matthew Farrell says Zicam has 73% share in the US zinc-containing wellness product market. It's acquiring marketer Matrixx Initiatives at a price almost 15 times Zicam brand’s projected 2021 EBITDA.

You may also be interested in...



Church & Dwight’s Consumer Health Product Sales Spared From Pandemic Plummet In Q2

C&D said sales of its brands including vitafusion, L’il Critters and PB8 supplements, Arm & Hammer, Aim and Close-Up toothpastes and Waterpick and Spinbrush power toothbrushes helped drive 8.8% growth to $386.4m for the personal and health care categories.

After US FDA Finds ‘Particularly Concerning’ GMP Problems, Homeopathic Firm Continues OTC Sales

A warning letter submitted by FDA Office of Regulatory Affairs’ Division of Pharmaceutical Quality Operations I in New Jersey notes that Homeocare Laboratories indicated to agency officials that it no longer is manufacturing OTC drugs.

FDA Adds Homeopathic Enforcement Details, Subtracts Compliance Policy Guide

Revised draft guidance identifies types of homeopathics posing "higher risks to public health." FDA withdraws 1988 compliance policy guide that allows homeopathic to be available even though they are not subject to pre-market approval or other review process agency imposes on all other drugs.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1131849

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel